Literature DB >> 9592033

Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels.

W González1, J M Soleilhac, M C Fournié-Zaluski, B P Roques, J B Michel.   

Abstract

We characterized neutral endopeptidase activity and protein in the three aortic layers and in corresponding cultured primary cells. Neutral endopeptidase was expressed in all three layers of rat aorta with higher protein level and activity in the adventitia than in the media and intimal endothelium. Neutral endopeptidase was also found in primary cultured fibroblasts, smooth muscle and endothelial cells derived from the corresponding layers. Neutral endopeptidase activity and protein were higher in the fibroblasts and smooth muscle cells than in endothelial cells. Neutral endopeptidase inhibition prevented atrial natriuretic peptide (ANP) degradation in endothelial and smooth muscle cells. It potentiated ANP-stimulated cyclic GMP production in these cells. Neutral endopeptidase inhibition also reduced bradykinin degradation and potentiated bradykinin-stimulated release of arachidonic acid in fibroblasts and endothelial cells. Our data demonstrate the presence and functional activity of neutral endopeptidase in all three cell layers of rat aorta as well as in primary cells of the vessel. The data suggest that local concentrations of vasoactive peptides in the vessel wall might be regulated by the neutral endopeptidase cleavage pathway in the immediate vicinity of their target cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592033     DOI: 10.1016/s0014-2999(98)00038-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

Review 1.  Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level.

Authors:  M J Dumoulin; D Lamontagne; G Molinaro; A Adam
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 2.  Vasopeptidase inhibition: a new direction in cardiovascular treatment.

Authors:  J R Asher; A J Naftilan
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

3.  Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice.

Authors:  Lawrence Coppey; Eric Davidson; Bao Lu; Craig Gerard; Mark Yorek
Journal:  Neuropharmacology       Date:  2010-09-16       Impact factor: 5.250

4.  Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.

Authors:  Eric P Davidson; Lawrence J Coppey; Amey Holmes; Brian Dake; Mark A Yorek
Journal:  Eur J Pharmacol       Date:  2011-07-28       Impact factor: 4.432

5.  Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.

Authors:  Christine L Oltman; Eric P Davidson; Lawrence J Coppey; Travis L Kleinschmidt; Brian Dake; Mark A Yorek
Journal:  Eur J Pharmacol       Date:  2010-10-30       Impact factor: 4.432

6.  Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells.

Authors:  Y Hayasaki-Kajiwara; N Naya; T Shimamura; T Iwasaki; M Nakajima
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

7.  The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy.

Authors:  Eric Davidson; Lawrence Coppey; Bao Lu; Victor Arballo; Nigel A Calcutt; Craig Gerard; Mark Yorek
Journal:  Exp Diabetes Res       Date:  2010-02-03

8.  Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction.

Authors:  C L Oltman; E P Davidson; L J Coppey; T L Kleinschmidt; M A Yorek
Journal:  Diabetes Obes Metab       Date:  2008-06-16       Impact factor: 6.577

9.  Bradykinin potentiation by ACE inhibitors: a matter of metabolism.

Authors:  Beril Tom; Andreas Dendorfer; René de Vries; Pramod R Saxena; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

10.  Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

Authors:  Wei-Chi Liao; Ole Vesterqvist; Carol Delaney; Mohammed Jemal; Irene Ferreira; Neville Ford; Brian Swanson; Howard Uderman
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.